- CVS Health (CVS, Financial) is set to boost earnings with a Medicare Advantage payment increase of 5.06%.
- Analysts offer an optimistic average price target of $71.56 for CVS Health Corp, indicating potential growth.
- GuruFocus estimates a significant upside with a forecasted GF Value of $87.74 for CVS.
CVS Health Corp (CVS) is on a promising path for financial growth as the Centers for Medicare & Medicaid Services have announced a substantial 5.06% increase in Medicare Advantage payments. This positive development is expected to significantly enhance CVS's earnings, particularly benefiting its Aetna unit with its highly-rated plans.
Wall Street Analysts' Insights
The investment community has expressed a favorable outlook for CVS Health Corp (CVS, Financial). According to the analysis of 24 financial experts, the average price target for CVS Health is set at $71.56. The high estimate of $80.00 and a more conservative low estimate of $48.01 illustrate the range of perspectives. The average target provides an anticipated upside of 3.76% from its current trading price of $68.97. For more comprehensive estimates, visit the CVS Health Corp (CVS) Forecast page.
The consensus among 29 brokerage firms positions CVS Health Corp with an average recommendation rating of 2.2, placing it in the "Outperform" category. This rating uses a scale where 1 is a Strong Buy and 5 is a Sell, reflecting analysts' confidence in CVS's market performance.
GuruFocus Valuation Perspective
GuruFocus's predictive capabilities suggest an estimated GF Value for CVS Health Corp (CVS, Financial) to reach $87.74 within a year. This projection indicates a robust upside potential of 27.21% from its current price of $68.97. The GF Value is derived from the stock's historical trading multiples, past business growth, and future business performance projections. For a detailed valuation and metrics overview, visit the CVS Health Corp (CVS) Summary page.
